Batoclimab (anti-FcRn (FCGRT & B2M)) is a human monoclonal antibody directed against the neonatal crystallizable fragment receptor (FcRn) with potential immunomodulating activity. It has the potential to be used in research on autoimmune diseases mediated by pathogenic IgG antibodies. MW: 143.76 kD.